tositumomab

BIOLOGICAL3 trials

Sponsors

SWOG Cancer Research Network, Duke University

Conditions

LymphomaLymphoma, B-Cell

Phase 2

Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma

CompletedNCT00577629

Duke UniversityLymphoma, B-Cell

Start: 2005-06-18End: 2016-11-03Updated: 2017-05-30

S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

CompletedNCT00770224

SWOG Cancer Research NetworkLymphoma

Start: 2009-04-30End: 2019-08-31Updated: 2019-08-28

Phase 3

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

CompletedNCT00006721

SWOG Cancer Research NetworkLymphoma

Start: 2001-03-01End: 2025-12-01Updated: 2026-03-16

Related Papers

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.

2026-02-26

Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma

Leukemia2026-02-19

System-Level Barriers to Uptake of Existing and Novel Radioimmunotherapy for People with Lymphoma

Blood2021-11-05

Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.

Journal of Clinical Oncology2020-05-201 citations

R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.

2018-01-2614 citations